In this article, we will be looking at the 13 best low risk high growth stocks to buy.
The current market is witnessing political chess moves, which are also affecting policy changes. There are whispers of a leadership change at the Federal Reserve, with speculation that Kevin Warsh could better align the policies of the Fed with the Treasury. These speculations intensify the expectations for rate cuts. According to CNBC, Warsh’s new Treasury-Fed accord could potentially result in synchronized policy efforts, leading to lowered borrowing costs and restored market confidence. The equity investors might find the shift more accommodative since growth stocks with lower downside exposure could shine brightest in such markets.
It’s not just today that investors are turning towards growth stocks. Historically, these stocks have proven their mettle in the market. Growth stocks have outpaced value stocks by an annualized 2.1% over the past three decades. At times, when rate-sensitive sectors and future cash flows regain, capturing the investors’ attention, the stocks’ performance increases, outpacing their value counterparts by a wider margin. With the Fed potentially turning toward cuts, we may be entering one of those cycles again.
Against this backdrop, this article explores 13 stocks that offer a rare combination of low volatility and strong upside potential. Stay with us as we count them down from 13 to 1. The top 5 might surprise you.
Image by Alexsander-777 from Pixabay
Our Methodology
When putting together our list of 13 best low-risk high-growth stocks to buy, we followed a few criteria. To filter the stocks with low beta, we have set the limit of 1. Stocks with a beta of more than 1 are not included in our list. Similarly, to ensure growth, we have included only those stocks with a positive EPS growth for the next 5 years. The candidates on our list are ranked based on beta.
All the data used in the article was taken from financial databases and analyst reports, with all information updated as of July 20, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13. Innovative Solutions and Support, Inc. (NASDAQ:ISSC)
Beta: 0.96
EPS next 5Y: 35.27%
Innovative Solutions and Support, Inc. (NASDAQ:ISSC) is among our list of 13 best low risk high growth stocks to buy. The company buzzes with insider activity following strong Q2 growth reported in the earnings call.
Innovative Solutions and Support, Inc. (NASDAQ:ISSC) is a Pennsylvania-based company, engaged in the business of designing, developing, manufacturing, and servicing advanced avionics systems. This includes flight guidance, autothrottles, air data computers, GPS units, and cockpit displays. The company integrates NextGen avionics and digital cockpit technologies to cater to the needs of commercial, business aviation, and military segments.
On May 14, 2025, Innovative Solutions and Support, Inc. (NASDAQ:ISSC) released its second quarter results for 2025. It highlighted a 100% growth in revenue owing to new military programs and legacy platforms. The company also reported an EBITDA growth of over 260% and a profit increase of over 300% from the previous year, while announcing a strong backlog of approximately $80 million.
Despite the strong quarter results, the company’s significant shareholder, Christopher Harborne, has been selling a notable amount of shares throughout June and July 2025. His latest sale was 217,508 shares, on July 1, 2025, for a transaction value of $2,975,091.
However, with the beta currently at 0.96 and an anticipated EPS growth of 35.27% for the next five years, Innovative Solutions and Support, Inc. (NASDAQ:ISSC) might still attract investors seeking a sturdy income at a lower risk.
12. Vital Farms, Inc. (NASDAQ:VITL)
Beta: 0.94
EPS next 5Y: 20.02%
Vital Farms, Inc. (NASDAQ:VITL) holds a spot among our list of 13 best low risk high growth stocks to buy. The company has reached more than 500 family farms, and the analysts are reaffirming their Buy rating on the stock.
Headquartered in Texas, Vital Farms, Inc. (NASDAQ:VITL) is a Certified B Corporation supplying pasture‑raised eggs, butter, and liquid eggs across U.S. supermarkets and foodservice channels. The company leverages an integrated model from production to packaging. This involves partnering with family farms for ethically sourced products.
In July 2025, the company announced achieving a significant milestone in its farming network. Vital Farms, Inc. (NASDAQ:VITL) has relied on family farms for ethically sourced eggs and egg products. This year, the company has reached over 500 family farms, surpassing the 2023 record of 300 family farms. Achieving the milestone signals the company’s strong commitment towards attracting and retaining family farmers across the Pasture Belt, to satisfy the growing demand for eggs.
Following the announcement, on July 17, 2025, Lake Street reiterated its Buy rating on the stock while maintaining a price target of $50.00, signaling its confidence in the company.
Vital Farms, Inc. (NASDAQ:VITL) combines a relatively low beta of 0.94 with a strong projected EPS growth of 20.02% over five years, suggesting a balance between risk and upside potential.
11. AAON, Inc. (NASDAQ:AAON)
Beta: 0.94
EPS next 5Y: 17.00%
AAON, Inc. (NASDAQ:AAON) earns a rank among our list of 13 best low risk high growth stocks to buy. Following loan expansion and comments at investor day, analysts are maintaining their Buy rating on the stock.
Oklahoma-based company, AAON, Inc. (NASDAQ:AAON) manufactures semi-custom HVAC equipment, including rooftop units, chillers, and air handlers. The company’s client base comprises commercial, industrial, and data‑center applications sectors. Founded in 1988, the company places importance on energy-efficient designs and operates various manufacturing facilities in the U.S.
On May 29, 2025, the company announced the expansion of its revolving commitment from $200 million to $500 million in the fifth amendment to its existing loan agreement. With a maturity date May 27, 2030, the new commitment is anticipated to increase the company’s financial flexibility.
Later, on June 10, 2025, AAON, Inc. (NASDAQ:AAON) saw a significant drop in its value by 15% following the comments made at the company’s investor day, including a 19.1% year-over-year decline in branded equipment, weak bookings, and supply chain issues.
In the days following the drop in stock value, Robert W. Baird and D.A. Davidson maintained their Buy rating on the stock, while Sidoti upgraded their rating from Neutral to Buy on AAON, Inc. (NASDAQ:AAON).
With a beta of 0.94 and impressive 17% EPS growth expected over five years, the company is a balanced growth candidate competing on our list of 13 best low-risk stocks.
10. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Beta: 0.84
EPS next 5Y: 25.93%
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) made its way to our list of 13 best low risk high growth stocks to buy. Mixed analysts’ sentiments for the stock, following the presentation of preclinical data for BP1.15205.
Headquartered in New Jersey, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company engaged in the process of developing therapies for rare neurological and sleep disorders. The company’s lead product, WAKIX® (pitolisant), treats excessive daytime sleepiness in narcolepsy, with additional pipeline treatments for Prader‑Willi Syndrome and myotonic dystrophy.
On June 11, 2025, the company announced new preclinical data for BP1.15205. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) claimed that this unique chemical scaffold is a potential best-in-class orexin-2 agonist. The company’s data indicates BP1.15205 has notable wake-promoting and cataplexy-suppressing effects in narcolepsy type-1 mouse models. With plans to initiate human trials in the later part of 2025, the company strengthens its foothold in the sleep-wake disorder treatment market, with BP1.15205.
Following this announcement, Mizuho Securities and H.C. Wainwright maintained their Buy rating on the stock. Deutsche Bank also keeps a Buy rating for the stock while raising the price target from $54 to $55. Goldman Sachs, however, sticks to their Hold rating on the company.
Amid these mixed ratings, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) maintains its position as a low-risk stock with high growth potential by offering a beta of 0.84 with an EPS growth of 25.93% for the next five years.
9. FitLife Brands, Inc. (NASDAQ:FTLF)
Beta: 0.80
EPS next 5Y: 20.44%
FitLife Brands, Inc. (NASDAQ:FTLF) holds a position in our list of 13 best low risk high growth stocks to buy. Analysts stick to their Buy rating on the stock amid mixed first-quarter results for 2025.
FitLife Brands, Inc. (NASDAQ:FTLF) is a developer and marketer of nutritional supplements. Based in Nebraska, the company targets weight loss, sports nutrition, and general wellness with its supplements. Its portfolio spans proprietary brands like NDS Nutrition, PMD Sports, SirenLabs, Nutrology, Dr. Tobias, and MusclePharm. In addition to retail channels, the company is notably active on online channels across the globe.
On May 15, 2025, the company announced its Q1 2025 earnings results. The results indicated an uptick of 5% in the total revenue of its brand Legacy FitLife, contributed by the 11% increase in online revenue and a 2% increase in wholesale revenue. On the other hand, the company’s total revenue for the quarter saw a 4% decline compared to the same quarter the previous year, owing to a fall in sales in other brands like Mimi’s Rock and MusclePharm.
Despite the mixed results, analysts like Lake Street and Roth MKM maintained their Buy rating on the stock, with a price target of $21.00 and $20.00, respectively.
FitLife Brands, Inc. (NASDAQ:FTLF) has a volatility indicated by its beta of 0.80 and an attractive EPS growth of 20.44% anticipated in the next 5 years, creating a balance between risk and reward.
8. PJT Partners Inc. (NYSE:PJT)
Beta: 0.78
EPS next 5Y: 16.93%
PJT Partners Inc. (NYSE:PJT) ranks among our list of 13 best low risk high growth stocks to buy. Consecutive price target raises on the stock, following major sales from the Director and the Annual Stockholders Meeting.
PJT Partners Inc. (NYSE:PJT) is a premier global advisory-focused investment bank operating from its headquarters in New York City. The company offers strategic advisory, restructuring, shareholder, and capital markets services. Formed in 2015 from the spin-off of Blackstone’s advisory business, the company has played an advisory role in transactions totalling more than $1 trillion.
On May 30, 2025, the company’s Director, Kievdi Don Cornwell, sold 20,000 of the company’s shares in a transaction valued at $3.01 million. Later, on June 18, 2025, the company held its Annual Stockholders Meeting, where three proposals were considered, including the election of directors to the board, executive compensation approval on an advisory basis, and ratification of Deloitte & Touche LLP as the independent public accounting company for 2025.
Further, as PJT Partners Inc. (NYSE:PJT)’s 1-month performance grew (18.48% as of July 20, 2025), Wolfe Research raised the company’s price target from $111 to $136, while keeping an underperform rating on the stock. Keefe Bruyette also raised the price target significantly from $161 to $196, with a Market Perform rating on the stock.
Currently, with a beta of 0.78 to suggest volatility, the company is expected to achieve an EPS growth of 16.93% in the upcoming 5-year period.
7. Pinterest, Inc. (NYSE:PINS)
Beta: 0.77
EPS next 5Y: 24.68%
Pinterest, Inc. (NYSE:PINS) ranks among our list of 13 best low risk high growth stocks to buy. The company bustles with analyst ratings and price target changes, following strong Q1 results and successful Ad tool adoption.
San Francisco-based company, Pinterest, Inc. (NYSE:PINS) is a visual discovery engine and social media platform. The company, with its smartphone application and web platforms, enables users to find, save, and shop ideas via virtual pinboards. From recipes and home decor to fashion and travel, the company’s database holds a wide range of collections to meet the needs of its users.
On May 8, 2025, the company released its Q1 2025 results. It indicated a record number of 570 million monthly active users (MAUs) across the globe and a 16% year-over-year increase in revenue.
The company’s Performance+ ad tool helped with the expansion of its lower-funnel shopping playbook internationally. As a result, the ad revenue for the quarter in Europe and other regions around the world went up by over 3 times faster than overall revenue growth in those areas.
Recently, following these developments, UBS and KeyBanc raised their price targets on the stock, while maintaining a Buy rating and an Overweight rating, respectively. UBS raised the price target from $44 to $50 while KeyBanc elevated it from $40 to $45 as of July 17, 2025.
Pinterest, Inc. (NYSE:PINS) offers a blend of low risk and high growth with its beta of 0.77 and a five-year anticipated EPS growth of 24.68%.
6. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)
Beta: 0.73
EPS next 5Y: 24.07%
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) earns a spot in our list of 13 best low risk high growth stocks to buy. The company witnesses its Buy rating maintained by analysts following a strategic partnership with Bloomberg.
Headquartered in Idaho, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) offers a cloud-native SaaS platform for automated investment data aggregation, reconciliation, accounting, reporting, and analytics. The company’s solutions support over $8.8 trillion in assets daily. In addition to insurers, asset managers, and corporates, the company also serves government clients.
On July 9, 2025, Clearwater Analytics Holdings, Inc. (NYSE:CWAN) announced entering into a strategic partnership with Bloomberg to deliver a front-to-back investment solution using an open and modular approach for asset owners and asset managers. The partnership involves combining Bloomberg’s front-office workflows with Clearwater’s back-office accounting platform, thereby achieving efficiency in streamlining investment management operations. The collaboration with Bloomberg also places the company favorably in front-office Request for Proposal discussions.
On June 11, 2025, Oppenheimer lowered the price target on the stock from $40 to $36 while Outperform rating. Morgan Stanley reflects the sentiment by maintaining a Buy rating and a price target of $36.
Investors interested in purchasing the stock must note the beta of Clearwater Analytics Holdings, Inc. (NYSE:CWAN), which currently stands at 0.73 alongside an EPS growth of 24.07% projected for the next 5 years.
5. Argan, Inc. (NYSE:AGX)
Beta: 0.58
EPS next 5Y: 17.00%
Argan, Inc. (NYSE:AGX) holds a rank among our list of 13 best low risk high growth stocks to buy. Amid strong quarter results and raised price targets, the company witnessed major sell-offs by its top executives in June.
Based in Maryland, the engineering, procurement, and construction holding company, Argan, Inc. (NYSE:AGX) engages in its business through subsidiaries like Gemma Power Systems. Specializing in power infrastructure, including natural gas and clean-energy plant construction, the company benefits from a robust project pipeline amid rising demand.
On June 4, 2025, the company reported its first quarter fiscal 2026 results, where it highlighted a 23% year-over-year increase in consolidated revenue reaching $193.7 million. Argan, Inc. (NYSE:AGX) also reported a record backlog of $1.9 billion as of April 30, 2025.
On June 5, 2025, while maintaining a Buy rating on the stock, Lake Street raised the price target on Argan, Inc. (NYSE:AGX) from $150 to $236, signaling immense confidence in the stock’s potential.
Following the target price increase, the company’s top executives, including the President, CEO, and Directors, sold a total of 118,000 shares in a total transaction valued at more than $25.58 million between June 11 and June 30, 2025.
Argan, Inc. (NYSE:AGX) keeps risk in check with a 0.58 beta, while the next five years could bring 17% EPS growth, suggesting a potential buy.
4. Eli Lilly and Company (NYSE:LLY)
Beta: 0.44
EPS next 5Y: 41.87%
Eli Lilly and Company (NYSE:LLY) finds its way into our list of 13 best low risk high growth stocks to buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics.
Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company’s notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries.
The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled ‘A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa’ and Phase 3 clinical study titled ‘A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.’ Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue.
Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions.
With a beta of 0.44 signaling the company’s resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list.
3. ADMA Biologics, Inc. (NASDAQ:ADMA)
Beta: 0.38
EPS next 5Y: 39.37%
ADMA Biologics, Inc. (NASDAQ:ADMA) generates a position among our list of 13 best low risk high growth stocks to buy. The company witnesses significant insider sales amid strong growth and strategic advances reported in the Q1 earnings report.
Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies. The company is engaged in the process of developing, manufacturing, and commercializing FDA-approved products, including ASCENIV, BIVIGAM, and Nabi-HB, to prevent and treat infectious diseases in immunodeficient and at-risk patients.
On May 7, 2025, the company reported its first quarter earnings report for 2025. With a solid 40% year-over-year increase in total revenues, reaching $114.8 million, the company raised its 2025 revenue guidance to more than $500 million. Additionally, the company has also announced a $500 million stock repurchase program, which reflects its confidence in its financial stability.
Later, on June 4, 2025, the company’s top executives started selling the company’s shares. Significant among them was the sales made by Director Steve Elms, who sold 425,621 shares, worth the value of $8,829,333.
Despite the potential hit these transactions could have had on the investor’s confidence, ADMA Biologics, Inc. (NASDAQ:ADMA)’s anticipated 5-year EPS growth continues to stand high at 39.37% while volatility remains low with a beta of 0.38.
2. Exelixis, Inc. (NASDAQ:EXEL)
Beta: 0.30
EPS next 5Y: 32.12%
Exelixis, Inc. (NASDAQ:EXEL) holds a rank among our list of 13 best low risk high growth stocks to buy. The company advances its studies following a significant rise in price targets from analysts.
Based in California, Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on discovering, developing, and commercializing oncology medicines. It is known for its work in oncology, specifically with small-molecule therapies and antibody-drug conjugates. The company’s key products include CABOMETYX (cabozantinib) and COMETRIQ. With these products, the company targets difficult-to-treat cancers such as renal cell and medullary thyroid carcinoma.
On June 10, 2025, Barclays, while keeping an Equal Weight rating on the stock, raised its price target from $29 to $40. Reflecting the sentiment, UBS also raised its price target on the stock from $38 to $43, while maintaining a Neutral rating.
With the new price targets indicating confidence in the company’s progress, Exelixis, Inc. (NASDAQ:EXEL) provided updates on its ongoing clinical studies. Study of XL092 has entered Phase 3, where its efficiency with nivolumab is tested in comparison to sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who have not received prior systemic anticancer therapy. The company also announced a Phase 1 clinical study on XL309 to estimate its safety and preliminary efficacy, both alone and in combination with olaparib, in treating advanced solid tumors.
In addition to these advances in cancer treatment, investors are also intrigued by the company’s low volatility, represented by the beta of 0.30 and the potential EPS growth of 32.12% in the next five years.
1. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Beta: 0.21
EPS next 5Y: 69.48%
Corcept Therapeutics Incorporated (NASDAQ:CORT) finds a spot in our list of the 13 best low risk high growth stocks to buy. Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment.
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company specializing in cortisol modulation by developing compounds that antagonize the glucocorticoid receptor. Based in California, the company treats Cushing’s syndrome with its commercial drug Korlym. The company advances a pipeline of over 30 clinical-stage molecules for endocrinology, oncology, metabolism, and neurology.
On July 14, 2025, the company announced that it had filed for a new drug application to the U.S. FDA for relacorilant. Relacorilant is a selective cortisol modulator for treating platinum-resistant ovarian cancer. The submission follows the positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. The trials indicated that relacorilant combined with nab-paclitaxel offers improved progression-free and overall survival, without increasing the safety burden of the patients. Since platinum-resistant ovarian cancer currently has limited therapies, the FDA approval for relacorilant has high expectations.
Amid this advancement in Corcept Therapeutics Incorporated (NASDAQ:CORT)’s relacorilant, Piper Sandler and H.C. Wainwright reiterated their Buy rating on the stock. Piper Sandler maintains a price target of $131 while H.C. Wainwright has set the price target at $145.
With an impressive projected 5-year EPS growth of 69.48% and a low beta of 0.21, Corcept Therapeutics Incorporated (NASDAQ:CORT) promises an attractive investment for those seeking high growth at low risk.
While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
